|
Mantle cell lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia.
|
30785921 |
2019 |
|
Mantle cell lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral inhibitor of Bruton tyrosine kinase, which is one of the key drugs used for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
|
30421802 |
2019 |
|
Mantle cell lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
This first-in-class inhibitor of Bruton's tyrosine kinase has become a standard treatment for patients with CLL and MCL.
|
30061088 |
2018 |
|
B-Cell Lymphomas
|
0.020 |
Biomarker
|
group |
BEFREE |
Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL).
|
31141631 |
2019 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.020 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia.
|
30785921 |
2019 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.020 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral inhibitor of Bruton tyrosine kinase, which is one of the key drugs used for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
|
30421802 |
2019 |
|
Small Lymphocytic Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
|
31512258 |
2019 |
|
Lymphoproliferative Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Atrial fibrillation is a side effect of ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase used for treatment of B-cell lymphoproliferative disorders.
|
29475534 |
2018 |
|
Lymphoproliferative Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple B-cell-mediated lymphoproliferative disorders.
|
28182323 |
2017 |
|
B-Cell Lymphomas
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Ibrutinib (Imbruvica<sup>®</sup>) is an oral irreversible inhibitor of Bruton's tyrosine kinase, a B-cell receptor (BCR) signalling kinase expressed by various haematopoietic cells, B-cell lymphomas and leukaemias.
|
28105602 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b/> In this issue Grommes and colleagues elegantly show that the irreversible inhibitor of Bruton tyrosine kinase, ibrutinib, promotes a high proportion of durable responses in primary central nervous system lymphoma, a type of diffuse large B-cell lymphoma (DLBCL), and also in secondary DLBCL relapsing to the central nervous system.
|
28864640 |
2017 |
|
Small Lymphocytic Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours.
|
28373262 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Deletions of CDKN2A/B (28%) and IBTK (23%) were frequent events in relapsed DLBCLs.
|
27276707 |
2016 |
|
Hodgkin Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase, has altered the treatment perspective of chronic lymphocytic leukemia and showed modest activity against several types of non-Hodgkin's lymphomas.
|
31142233 |
2020 |
|
Hematologic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Ibrutinib is an oral inhibitor of Bruton's tyrosine kinase that is used for a variety of B cell hematological malignancies.
|
31216242 |
2020 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fenebrutinib (GDC-0853) is an orally administered small molecule inhibitor of Bruton's tyrosine kinase being investigated for treatment of rheumatoid arthritis in patients with inadequate responses to methotrexate (MTX).
|
31371481 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, an inhibitor of Bruton tyrosine kinase (BTK), has shown promising pharmacologic effects in acute myeloid leukemia (AML).
|
31310800 |
2019 |
|
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Here, we report that loss of the murine Ibtk gene raises survival and delays tumor onset in Eμ-myc transgenic mice, a preclinical model of Myc-driven lymphoma.
|
30975981 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia.
|
30785921 |
2019 |
|
Pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data indicate that the Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses during acute pulmonary inflammation evoked by LTA and antibiotic-treated pneumococcal pneumonia and suggest that ibrutinib has the potential to inhibit ongoing lung inflammation in an acute infectious setting.
|
30646846 |
2019 |
|
Lobar Pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data indicate that the Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses during acute pulmonary inflammation evoked by LTA and antibiotic-treated pneumococcal pneumonia and suggest that ibrutinib has the potential to inhibit ongoing lung inflammation in an acute infectious setting.
|
30646846 |
2019 |
|
Streptococcal pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data indicate that the Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses during acute pulmonary inflammation evoked by LTA and antibiotic-treated pneumococcal pneumonia and suggest that ibrutinib has the potential to inhibit ongoing lung inflammation in an acute infectious setting.
|
30646846 |
2019 |
|
Malignant lymphoma - lymphoplasmacytic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia.
|
30785921 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
However, the role of IBTK in tumorigenesis has not been elucidated.
|
30975981 |
2019 |
|
Leukemogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
|
30975981 |
2019 |